⚕ GalenOps CRO console
← SITE011 (ITA)

SITE011-0049

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE011 (ITA) (Dr. Jansen) · consented 2022-05-01
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-11 (study day 5); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 24); relationship: N

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-07-03 (study day 58); relationship: N

moderate assessed 2026-08-18

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 235); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-01-13 (study day 252); relationship: Y

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-11 (study day 309); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-04-12 (study day 341); relationship: Y

severe assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-07 (study day 366); relationship: N

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-10-24 (study day 536); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.